NEW YORK (Reuters Health)—Guselkumab may be effective in patients who have psoriatic arthritis (PsA) with axial symptoms, a post-hoc analysis of data from two randomized controlled trials suggests.1 “Because PsA is a heterogeneous disease that manifests as various symptoms, treatment choices should involve consideration of all relevant domains of disease for each individual patient,” researchers…
PRSYM—At its heart, the practice of medicine in all forms is specifically centered on delivering compassionate, thoughtful and evidence-based clinical care. In the world of pediatric rheumatology, a range of issues, such as chronic pain, reproductive health and transitioning to adult providers, are of utmost importance to patients and physicians alike. These topics were addressed…
Patients’ questions about pro- and anti-inflammatory diets can be challenging to address. Dr. Elena Nikiphorou provided insight into the latest research regarding the role of diet in rheumatic and musculoskeletal diseases.
NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1 His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he…
NEW YORK (Reuters Health)—A six-month assessment of children with pediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS) show generally favorable outcomes, but also a range of lingering issues. Cardiac, gastrointestinal, renal, hematology and otolaryngology problems largely resolved at six months, but muscular fatigue and emotional lability were common. Long-term, serious end-organ damage occurred…